Scientists test new ongoing treatment for Parkinson’s disease. Researchers behind an experimental treatment for Parkinson’s disease believe that the approach could be a breakthrough therapeutic strategy for neurological conditions. The treatment uses an innovative mechanism: administering the drug directly into the brain through implanted ports.
In a series of ongoing clinical trials, specialists have started investigating the new new treatment for Parkinson’s disease. The initial trial was conducted by a group of scientists from different institutions across the United Kingdom and Canada, the University of British Columbia in Vancouver, Canada and the University of Bristol and Cardiff University in the U.K.
The scientists aimed to restore brain cells in people who had diagnosed with Parkinson’s disease. By increasing the levels of neurotrophic factor (GDNF) derived by glial cell line, the team tried to reinstate brain cells. GDNF is form of protein that backs neuronal health.
The researchers explains their study which now appears in the Journal of Parkinson’s Disease. They used a novel approach using a port.
The participants involved in this research agreed to have a port implanted into their skills. With this method, the researchers wanted to restore the drug straight into their brains. The team then found that the participants who had received the GDNF treatment reported an overall improvement in the brain region called putamen. The area contains dopamine-producing cells.
“The spatial and relative magnitude of the improvement in the brain scans is beyond anything seen previously in trials of surgically delivered growth-factor treatments for Parkinson’s,” notes study’s principal investigator Alan Whone.